Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2015 · 10-Q
Revenue$0.00$0.00— vs Q3 2014 Net Income-$1.20M-$1.20MN/M vs Q3 2014 EPS Diluted$0.00$0.00N/M vs Q3 2014 Operating Income-$1,202,061N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Sep 30, 2015 · filed Nov 4, 2015 · 35 d after period end